| 2026-08-13 | Press release | Press release |
| 2026-08-13 | Press release | ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2 |
| 2026-08-03 | Press release | Press release |
| 2026-08-03 | Press release | ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Re |
| 2026-07-07 | Press release | Press release |
| 2026-07-07 | Press release | ARS Pharmaceuticals Announces CEO Succession |
| 2026-06-24 | Press release | Press release |
| 2026-06-24 | Press release | ARS Pharmaceuticals Provides Commercial and Financial Updates |
| 2026-06-04 | Press release | Press release |
| 2026-06-04 | Press release | Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies |
| 2026-05-15 | Press release | Press release |
| 2026-05-15 | Press release | ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update |
| 2026-05-13 | Press release | Press release |
| 2026-05-13 | Press release | ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President |
| 2026-05-07 | Press release | Press release |
| 2026-05-07 | Press release | ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results |
| 2026-04-15 | Press release | Press release |
| 2026-04-15 | Press release | neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Re |
| 2026-03-27 | Press release | Press release |
| 2026-03-27 | Press release | ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label |
| 2026-03-09 | Press release | Press release |
| 2026-03-09 | Press release | ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal |
| 2026-02-23 | Press release | Press release |
| 2026-02-23 | Press release | ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results an |
| 2026-02-10 | Press release | Press release |
| 2026-02-10 | Press release | ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 20 |
| 2026-02-02 | Press release | Press release |
| 2026-02-02 | Press release | EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Re |
| 2026-01-21 | Press release | Press release |
| 2026-01-21 | Press release | California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergen |
| Press release | ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) |
| Press release | ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results |
| Press release | ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epineph |
| Press release | ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results |
| Press release | ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of ne |
| Press release | ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results |